FDA's Fears Realized: Sponsors Pitching Investors 'Sarepta Model'
Investor compares the development construct to homeopathic medicine.
You may also be interested in...
The Eteplirsen Precedent: No Denying It – So Let’s Define It
US FDA allowing Sarepta to seek accelerated approval for follow-on DMD agent – following 'precedent' set by eteplirsen. Now the new challenge is to define exactly what that precedent is.
How Accelerated Approval Works – And How It Doesn't
PTC Therapeutics argues FDA did not apply the same standard to Translarna in Duchenne muscular dystrophy as previous DMD products, but FDA says accelerated approval was not possible because of negative efficacy data.
Top 16 From '16: Pink Sheet's Most Popular Stories
Big developments, key biopharma trends, and other topics that most intrigued and impacted our readers in 2016.